Cargando…
Acquired factor V inhibitor with erythema and eosinophilia in a patient with end-stage renal disease
Autoimmune factor V deficiency (AiFVD) is a rare bleeding disorder caused by factor V inhibitors. In this report, we present the case of an 89-year-old man who developed bleeding tendency during surgery to create arteriovenous fistula for hemodialysis. The bleeding tendency developed with prolongati...
Autores principales: | , , , , , , , , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Springer Nature Singapore
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9361254/ https://www.ncbi.nlm.nih.gov/pubmed/35943699 http://dx.doi.org/10.1007/s13730-022-00725-y |
_version_ | 1784764492253495296 |
---|---|
author | Katsuren, Eisuke Kohagura, Kentaro Kinjyo, Takanori Zamami, Ryo Nakamura, Takuto Oshiro, Nanako Sunagawa, Yoshitsugu Omine, Kumiko Kudo, Yuki Shinzato, Yuki Osaki, Tsukasa Souri, Masayoshi Ichinose, Akitada Yamazato, Masanobu Ishida, Akio Ohya, Yusuke |
author_facet | Katsuren, Eisuke Kohagura, Kentaro Kinjyo, Takanori Zamami, Ryo Nakamura, Takuto Oshiro, Nanako Sunagawa, Yoshitsugu Omine, Kumiko Kudo, Yuki Shinzato, Yuki Osaki, Tsukasa Souri, Masayoshi Ichinose, Akitada Yamazato, Masanobu Ishida, Akio Ohya, Yusuke |
author_sort | Katsuren, Eisuke |
collection | PubMed |
description | Autoimmune factor V deficiency (AiFVD) is a rare bleeding disorder caused by factor V inhibitors. In this report, we present the case of an 89-year-old man who developed bleeding tendency during surgery to create arteriovenous fistula for hemodialysis. The bleeding tendency developed with prolongation of activated partial thromboplastin and prothrombin time, following drug-induced eruption and eosinophilia. Significant reduction in coagulation factor activity and inhibitory pattern in cross-mixing tests suggested the presence of inhibitors to coagulation factors. Subsequently, we detected a factor V inhibitor and anti-factor V autoantibodies was confirmed using enzyme-linked immunosorbent assay with purified human plasma factor V. Thus, the patient was ‘definitely diagnosed’ with AiFVD in accordance with the diagnostic criteria enacted by the Japanese Ministry of Health, Labor, and Welfare. The bleeding tendency improved after initiating oral prednisolone 50 mg (1 mg/kg) followed by normalization of activated partial thromboplastin time and prothrombin time at the 34th day. After improving the coagulation system prolongation, the inhibitor and autoantibodies has been eradicated. Since it is suggested that drug-induced immune response can cause AiFVD, AiFVD should be considered in patients who undergo hemodialysis and develop failure of hemostasis and drug-induced eruption. |
format | Online Article Text |
id | pubmed-9361254 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2022 |
publisher | Springer Nature Singapore |
record_format | MEDLINE/PubMed |
spelling | pubmed-93612542022-08-09 Acquired factor V inhibitor with erythema and eosinophilia in a patient with end-stage renal disease Katsuren, Eisuke Kohagura, Kentaro Kinjyo, Takanori Zamami, Ryo Nakamura, Takuto Oshiro, Nanako Sunagawa, Yoshitsugu Omine, Kumiko Kudo, Yuki Shinzato, Yuki Osaki, Tsukasa Souri, Masayoshi Ichinose, Akitada Yamazato, Masanobu Ishida, Akio Ohya, Yusuke CEN Case Rep Case Report Autoimmune factor V deficiency (AiFVD) is a rare bleeding disorder caused by factor V inhibitors. In this report, we present the case of an 89-year-old man who developed bleeding tendency during surgery to create arteriovenous fistula for hemodialysis. The bleeding tendency developed with prolongation of activated partial thromboplastin and prothrombin time, following drug-induced eruption and eosinophilia. Significant reduction in coagulation factor activity and inhibitory pattern in cross-mixing tests suggested the presence of inhibitors to coagulation factors. Subsequently, we detected a factor V inhibitor and anti-factor V autoantibodies was confirmed using enzyme-linked immunosorbent assay with purified human plasma factor V. Thus, the patient was ‘definitely diagnosed’ with AiFVD in accordance with the diagnostic criteria enacted by the Japanese Ministry of Health, Labor, and Welfare. The bleeding tendency improved after initiating oral prednisolone 50 mg (1 mg/kg) followed by normalization of activated partial thromboplastin time and prothrombin time at the 34th day. After improving the coagulation system prolongation, the inhibitor and autoantibodies has been eradicated. Since it is suggested that drug-induced immune response can cause AiFVD, AiFVD should be considered in patients who undergo hemodialysis and develop failure of hemostasis and drug-induced eruption. Springer Nature Singapore 2022-08-09 /pmc/articles/PMC9361254/ /pubmed/35943699 http://dx.doi.org/10.1007/s13730-022-00725-y Text en © The Author(s) under exclusive licence to The Japan Society of Nephrology 2022, Springer Nature or its licensor holds exclusive rights to this article under a publishing agreement with the author(s) or other rightsholder(s); author self-archiving of the accepted manuscript version of this article is solely governed by the terms of such publishing agreement and applicable law. |
spellingShingle | Case Report Katsuren, Eisuke Kohagura, Kentaro Kinjyo, Takanori Zamami, Ryo Nakamura, Takuto Oshiro, Nanako Sunagawa, Yoshitsugu Omine, Kumiko Kudo, Yuki Shinzato, Yuki Osaki, Tsukasa Souri, Masayoshi Ichinose, Akitada Yamazato, Masanobu Ishida, Akio Ohya, Yusuke Acquired factor V inhibitor with erythema and eosinophilia in a patient with end-stage renal disease |
title | Acquired factor V inhibitor with erythema and eosinophilia in a patient with end-stage renal disease |
title_full | Acquired factor V inhibitor with erythema and eosinophilia in a patient with end-stage renal disease |
title_fullStr | Acquired factor V inhibitor with erythema and eosinophilia in a patient with end-stage renal disease |
title_full_unstemmed | Acquired factor V inhibitor with erythema and eosinophilia in a patient with end-stage renal disease |
title_short | Acquired factor V inhibitor with erythema and eosinophilia in a patient with end-stage renal disease |
title_sort | acquired factor v inhibitor with erythema and eosinophilia in a patient with end-stage renal disease |
topic | Case Report |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9361254/ https://www.ncbi.nlm.nih.gov/pubmed/35943699 http://dx.doi.org/10.1007/s13730-022-00725-y |
work_keys_str_mv | AT katsureneisuke acquiredfactorvinhibitorwitherythemaandeosinophiliainapatientwithendstagerenaldisease AT kohagurakentaro acquiredfactorvinhibitorwitherythemaandeosinophiliainapatientwithendstagerenaldisease AT kinjyotakanori acquiredfactorvinhibitorwitherythemaandeosinophiliainapatientwithendstagerenaldisease AT zamamiryo acquiredfactorvinhibitorwitherythemaandeosinophiliainapatientwithendstagerenaldisease AT nakamuratakuto acquiredfactorvinhibitorwitherythemaandeosinophiliainapatientwithendstagerenaldisease AT oshironanako acquiredfactorvinhibitorwitherythemaandeosinophiliainapatientwithendstagerenaldisease AT sunagawayoshitsugu acquiredfactorvinhibitorwitherythemaandeosinophiliainapatientwithendstagerenaldisease AT ominekumiko acquiredfactorvinhibitorwitherythemaandeosinophiliainapatientwithendstagerenaldisease AT kudoyuki acquiredfactorvinhibitorwitherythemaandeosinophiliainapatientwithendstagerenaldisease AT shinzatoyuki acquiredfactorvinhibitorwitherythemaandeosinophiliainapatientwithendstagerenaldisease AT osakitsukasa acquiredfactorvinhibitorwitherythemaandeosinophiliainapatientwithendstagerenaldisease AT sourimasayoshi acquiredfactorvinhibitorwitherythemaandeosinophiliainapatientwithendstagerenaldisease AT ichinoseakitada acquiredfactorvinhibitorwitherythemaandeosinophiliainapatientwithendstagerenaldisease AT yamazatomasanobu acquiredfactorvinhibitorwitherythemaandeosinophiliainapatientwithendstagerenaldisease AT ishidaakio acquiredfactorvinhibitorwitherythemaandeosinophiliainapatientwithendstagerenaldisease AT ohyayusuke acquiredfactorvinhibitorwitherythemaandeosinophiliainapatientwithendstagerenaldisease |